Every Life Deserves Attention

A pioneer in Epigenome Editing

The timing, location, and abundance of the approximately 20,000 proteins that compose our bodies are meticulously regulated, much like a symphony orchestra. This precise coordination is orchestrated by a gene control system known as the epigenome. When this system malfunctions, it can lead to disease. CRISPR-GNDM® offers the ability to selectively target and regulate the epigenomes of specific genes, enabling us to restore harmony and treat various ailments.

Press Releases

Media 04/01/2025

Modalis was featured as one of the few epigenome editing therapeutics companies challenging CNS diseases (central nerve system diseases), which are difficult to develop therapeutics for with other modalities and have high unmet medical needs.

Media 03/28/2025

An interview article with Dr. Seth Levy, Senior Director Manufacturing, was published in Outsource Pharma

Media 03/06/2025

Our MDL-207 approach to Dravet Syndrome was featured in BioCentury.

News 02/13/2025

Modalis Reports 2024 Financial Results and Operational Highlights

News 11/07/2024

Modalis Therapeutics Reports Operational Highlights and Third Quarter 2024 Financial Results

Press Releases

Recent IR filings

IR filings

Genetic Disorders

Genetic disorders are often caused by errors or mutations in DNA sequence, making gene-level intervention essential to develop therapeutic cures. Gene therapies can rescue disease-associated mutations by delivering corrective DNA or RNA sequences through cell-targeting viral vectors and nanoparticles.

More Details

CRISPR/Cas9 system

Genome editing is a new area of gene therapy, made possible by the development of CRISPR technology. CRISPR can precisely target faulty parts of our DNA, either cutting them out or inserting the correct genes, making genome editing a practical solution for treating genetic diseases.

More Details

Epigenome Editing

Epigenome editing is a technology that regulates the expression of specific genes without altering the DNA sequence or causing double-strand breaks. It allows genes to be turned ON or OFF by Chemical modification of DNA and histones.

More Details

CRISPR-GNDM Technology

CRISPR-GNDM® is an advanced epigenome editing technology developed by our company, designed to treat diseases by efficiently delivering a compact epigenome editor. This editor can be packed in AAV vectors for delivery to target cells, enabling the selective activation or suppression of specific genes with remarkable precision.

More Details

BUSINESS

Multilayered deployment of hybrid in-house and collaborative development pipelines

The in-house pipelines are candidate therapeutics which the company develops using CRISPR-GNDM® technology with its own funding, and at a certain stage, the baton is passed to the partner for subsequent development and sales through a licensing agreement. Collaborative pipelines are ones in which the company develops therapeutic drugs using CRISPR-GNDM® technology with a partner company for a target that the partner selected or that both parties agree on. The partner then takes over the development later on.

More Details

PIPELINE